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Summary
 
Background
 
In patients with multiple endocrine neoplasia type 1
(MEN1), expression of somatostatin receptor (SST) in parathyroid
adenomas and effectiveness of therapy with somatostatin analogues
on primary hyperparathyroidism (PHP) have been scarcely investigated.
 
Objective
 
To evaluate the effects of depot long acting octreotide
(OCT-LAR) in patients with MEN1-related PHP.
 
Patients
 
Eight patients with a genetically confirmed MEN1,
presenting both PHP and duodeno-pancreatic neuroendocrine
tumours (NET), were enrolled.
 
Design
 
The initial treatment was OCT-LAR 30 mg every 4 weeks.
This therapy was established to stabilize the duodeno-pancreatic
NET before to perform parathyroidectomy for PHP. Before
OCT-LAR therapy, a SST scintigraphy was performed in all patients.
SST subtype 2A immunohistochemistry was performed on parathyroid
tumour samples from three patients undergone parathyroidectomy
after OCT-LAR therapy.
 
Measurements
 
Serum concentrations of PTH, calcium and
phosphorus as well as the 24-h urine calcium :  creatinine ratio and
the renal threshold phosphate concentration were evaluated before
and after OCT-LAR.
 
Results
 
After OCT-LAR therapy, hypercalcaemia and hypercalciuria
normalized in 75% and 62·5% of patients, respectively, and serum
phosphorus and renal threshold phosphate significantly increased.
Serum PTH concentrations significantly decreased in all patients and
normalized in two of them. SST subtype 2A immunostaining was
found in all parathyroid adenomas investigated, while SST scintigraphy
showed a positive parathyroid tumour uptake in three of eight
patients (37·5%).
 
Conclusion
 
Six months of OCT-LAR therapy controlled
hypercalcaemia and hypercalciuria in two-thirds of patients with
MEN1-related PHP. Direct OCT-LAR effects mediated by binding
to SST expression on parathyroid tumour cells are likely the main
mechanism to explain the activity of this compound on calcium and
phosphorus abnormalities in MEN1 PHP.
(Received 4 March 2008; returned for revision 7 April 2008; finally 
 
revised 11 April 2008; accepted 3 May 2008)
 
Introduction
 
Multiple endocrine neoplasia type 1 (MEN1) is characterized by a
variable phenotypic expressiveness; primary hyperparathyroidism
(PHP), however, occurs in 90–100% of patients and is the MEN1
earliest manifestation in 90% of the cases.
 
1–3
 
 A latent PHP occurs in
the vast majority of patients, even when a duodeno-pancreatic
neuroendocrine tumour (NET) or a pituitary adenoma are the first
MEN1 clinical manifestations.
Nowadays, no effective medical therapy for PHP is available,
although preliminary studies reported cinacalcet, a calcimimetic
compound, to be effective in normalizing hypercalcaemia in patients
with sporadic PHP.
 
4,5
 
 Somatostatin analogues (SSA) are compounds
known to control hormone excess and to stabilize tumour growth
in several type of NET.
 
6,7
 
 In patients with MEN1 they are used to
target duodeno-pancreatic NET and/or pituitary adenomas.
 
8,9
 
Few and discordant data have been reported on the effects of SSA
in PHP. Preliminary clinical experience with subcutaneous octreotide
200 
 
μ
 
g daily reportedly improved hypercalciuria but was ineffective
on hypercalcaemia and PTH levels.
 
10,11
 
 Similarly, no effect was
observed after an acute test with octreotide in 40 patients with PHP.
 
12
 
More recently, one of two patients with MEN1-related PHP had
decreased PTH levels during a 6-month treatment with subcutaneous
octreotide.
 
13
 
It has been demonstrated in other NET models that depot
octreotide (OCT-LAR) is much more effective than its short-acting
formulation in controlling hormone excess.
 
14
 
The present study was designed to investigate whether therapy
with OCT-LAR might improve PHP in patients with MEN1.
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Patients and methods
 
Patients
 
Among 18 patients with MEN1-related PHP who were admitted to
the Department of Endocrinology of the ‘Federico II’ University of
Naples from 1 January 2004 to 31 March 2007, eight patients with
both PHP and duodeno-pancreatic NET were included in the study.
These patients (four males, four females) had a mean age of
41·6 ± 5·0 years (range: 19–66). All were positive to the MEN1 gene
mutation analysis. At diagnosis, MEN1 clinical features included
PHP with multiparathyroid gland involvement, and one or more
NET in the duodeno-pancreatic tract. NET were stable in five
patients and progressive in three. One patient had liver metastases.
Chromogranin-A and gastrin excess were detected in all and five
patients, respectively. Therefore, all patients were susceptible to be
treated with OCT-LAR for the duodeno-pancreatic NET and, at the
same time, all of them were studied for the effects of OCT-LAR on
PHP which also affected these patients. All patients had normal renal
function as expressed by creatinine clearance.
OCT-LAR therapy was given at a dose of 30 mg i.m. every 4 weeks.
Parathyroid surgery was planned when NET were stabilized. Thus,
in all of the patients we evaluated the effects of OCT-LAR on PHP
by measuring serum PTH, calcium and phosphorus levels and
urinary excretion of calcium and phosphorus before and 3 and
6 months after the beginning of the OCT-LAR treatment. All
patients were advised to increase water intake to at least 3 litres a day.
 
Biochemical evaluation
 
Blood samples were collected for measurement of serum calcium,
phosphorus and PTH at baseline and at each study visit after an
overnight fast. Urine samples were collected over 24 h and after an
overnight fast at baseline and at each visit for the measurement of
calcium and phosphorus excretion; 24-h urine calcium excretion
was factored by creatinine excretion. To evaluate renal tubular
re-absorption of phosphate, the renal threshold for phosphate
(maximal transport of phosphate/GFR, normal 0·75–1·37 mmol/l
glomerular filtrate; 2·3–4·2 mg/l glomerular filtrate) was determined
at baseline and at each study visit by using the normogram by Walton
and Bijvoet.
 
15
 
Somatostatin receptor scintigraphy
 
In vivo
 
 evaluation of somatostatin receptor (SST) expression was
performed in all patients at the time of diagnosis by using radio-
receptor whole-body scan with [
 
111
 
In-DTPA-D-Phe
 
1
 
]octreotide, as
previously described.
 
16
 
Immunohistochemistry
 
After 6 months of OCT-LAR therapy, three out of the eight patients
underwent parathyroidectomy. In these patients, SST subtype 2A
(SST2A) expression was evaluated on parathyroid tumour samples
by using immunohistochemistry. Immunohistochemical staining
was performed on 4 
 
μ
 
m thick serial sections of each adenoma
mounted on pretreated slides with poly 
 
l
 
-Lysine. Sections were
pretreated with a heat-induced antigen retrieval technique, with
incubation in a 650 W microwave oven (three sequential step a
10 min each in citrate buffer (pH 6·0) 10 m
 
m
 
), for antigen unmasking
and then incubated for 20 min at room temperature with 0·3%
hydrogen peroxide in methanol, to quench the endogenous peroxidases.
After successive washings in PBS (saline phosphate tampon)
(Bio-Optica M107, Milan Italy) for 20 min. Further incubation with
nonimmune mouse serum (1 : 20, Dakopatts, Hamburg, Germany)
diluted in PBS-bovine serum albumin (1%) for 25 min was
performed to prevent nonspecific immunostaining. After washing
three times in PBS, immunostaining was performed by using the
anti-SST2A (BioTrend, Cologne, Germany, code SS-800) as primary
antibody. Incubation was carried at 37 
 
°
 
C overnight. After incubation
and three washing cycles in PBS, sections were incubated with
biotinyled link antibodies and peroxidase-labelled streptavidine
(LSAB-HRP, Dako, Italy). 3,3 Diaminobenzidine (DAB, Vector
Laboratories, Burlingame, CA) with 0·3% H
 
2
 
O
 
2
 
 was used as substrate
chromogen solution. After nuclear counterstaining with Mayer’s
haematoxylin, sections were mounted with synthetic medium
(Entellan, Dermstad, Germany). Sections of pancreatic islets and
breast cancer were used as positive controls. The negative controls
were obtained by using mouse or rabbit serum with no specific
reactivity. A semiquantitative scoring system was used, as previously
described.
 
17
 
 The subcellular localization and the extent of the staining
were both considered as follows: score 0: absence of immuno-
reactivity; score 1: cytoplasm immunoreactivity only, either focal
or diffuse; score 2: membranous reactivity in < 50% of tumour
cells, irrespective of the presence of cytoplasm staining; score
3: circumferential membranous reactivity in > 50% of tumour
cells, irrespective of the presence of cytoplasm staining. The
immunohistochemical findings were analysed by two pathologists
(MLDBDC; GM) independently. There was a complete agreement
in the interpretation of the immunoreactivity between the two
pathologists.
 
Statistical analysis
 
The statistical analysis was performed by 
 
spss
 
 for Windows version
10 (SPSS Inc., Chicago, IL). Data are reported as mean ± SEM.
The significance was set at 5%. The comparison between the
numerical data was performed by Student’s 
 
t
 
-test. The comparison
between the categorical data was performed by 
 
χ
 
2
 
-test with Yates
correction, Fisher exact test as appropriate. The correlation study
was performed by the linear regression analysis calculating the
Pearson’s coefficient.
 
Results
 
At diagnosis, all patients had hypercalcaemia, hypercalciuria,
hypophosphataemia, high serum PTH and evidence of enlargement
of at least one parathyroid at the colour-Doppler neck ultrasono-
graphy and parathyroid scintigraphy. In three patients (37·5%), SST
scintigraphy showed positive parathyroid tumour uptake (Table 1).
At immunohistochemistry, SST2A was positive in all parathyroid
adenomas evaluated: score 3 in one (patient number 7, Table 1) and
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score 2 in two cases (patient numbers 3 and 6, Table 1) (Fig. 1).
SST2A immunoreactivity was specific as revealed by negative control
experiments. SST scintigraphy was positive in the patient with score
3 SST2A immunostaining and negative in those with score 2 SST2A
immunostaining.
Before OCT-LAR therapy, serum PTH, calcium and phosphorus
concentrations did not significantly change during a 3 month
follow-up period (Figs 2 and 3).
After the introduction of OCT-LAR therapy, serum calcium
progressively decreased in all patients (Fig. 3). After 3 months of
therapy, serum calcium was significantly decreased while phosphorus
was significantly increased when compared to baseline. No significant
change occurred in serum PTH within 3 months (Fig. 2). After
6 months of therapy, no further variation was observed in serum
calcium and phosphorus as compared to 3 month follow-up. Serum
PTH concentrations were significantly decreased when compared to
baseline (Fig. 2).
The 24-h urine calcium :  creatinine ratio and the renal threshold
phosphate concentration were unchanged during the 3-month
observation before OCT-LAR administration. During OCT-LAR
therapy, the urine calcium : creatinine ratio progressively decreased
in all patients (Fig. 3). Three months after OCT-LAR treatment, the
calcium : creatinine ratio significantly decreased. After 6 months, a
further significant decrease occurred (Fig. 2). The renal threshold
phosphate concentration significantly increased as compared to
baseline, 3 months after OCT-LAR therapy; a further but not significant
increase was observed at 6 month evaluation (Fig. 2).
At the end of the 6 month follow-up, serum and urinary calcium
levels were within the normal range in 6 (75%) and 5 (62·5%)
of 8 patients, respectively, while PTH plasma levels normalized in
2 of 8 patients (25%).
 
Discussion
 
PHP is the most common endocrine disorder associated with MEN1
syndrome.
 
1–3
 
 The only curative therapy is surgery, which is
required to remove all hyperfunctioning parathyroid tissue. Since
MEN1-related PHP affects all the parathyroid tissue, resulting in
multiple parathyroid adenomas or diffuse hyperplasia, surgical
treatment for MEN1 patients should be a near-total or total parathy-
roidectomy.
 
18,19
 
 After curative surgery, hypoparathyroidism
may occur and hyperparathyroidism may relapse later as well,
resulting in decreased quality of life and difficult control of calcium
homeostasis.
 
19,20
Table 1. Clinical, biochemical and morpho-functional profile in 8 patients with MEN1-dependent primary hyperparathyroidism
Age/gender
Somatostatin 
receptor scintigraphy
Serum PTH pmol/l 
(normal, 1–7·5)
Serum calcium mmol/l 
(normal, 2·20–2·58)
Serum phosphorus 
mmol/l (0·80–1·60)
24-h urine calcium : 
creatinine mg ratio
Renal phosphate 
threshold mmol/l GF
1. 45/M Negative 10·8 2·74 0·74 0·63 0·38
2. 42/F Negative 9·5 2·55 0·81 0·61 0·75
3. 35/M Negative 13·3 2·79 0·87 0·45 0·52
4. 32/F Negative 9·2 2·79 0·84 0·91 0·70
5. 66/M Positive 10·2 3·01 0·90 0·55 0·73
6. 19/F Negative 7·6 2·77 0·84 0·57 0·75
7. 41/M Positive 8·8 2·74 0·94 0·35 0·80
8. 53/F Positive 31·2 2·79 0·84 0·58 0·60
Fig. 1 (a) Photomicrographs: H&E staining showing hypercellular, homogeneus, well-vascularized and sepimented tumour tissue (Magnification × 100). 
(b) Somatostatin receptor subtype 2A immunostaining showing diffuse cytoplasmic pattern with cell membrane expression in more than 50% of tumour 
cells (Magnification × 400).
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Nowadays, there is no official indication for medical therapy
alternative to surgery in PHP. Cinacalcet is a calcimimetic compound
really promising for treating PHP: in preliminary studies it normalized
hypercalcaemia and decreased PTH levels in several patients with
sporadic PHP.
 
4,5
 
 However, these first observations did not include
patients with MEN1 PHP. These patients are considered to be more
difficult to manage, because of the involvement of the entire
parathyroid tissue. Furthermore, the long-term efficacy and safety
of cinacalcet has not been studied so far, and prospective randomized
studies have to be performed in order to validate its usefulness in
PHP.
If calcimimetic compounds are still experimental in MEN1
patients, SSA are effectively used to manage different types of NET
in these patients. SSA are a helpful tool to treat both gastro-
entero-pancreatic NET and pituitary adenomas.
 
6–9
 
 These tumours
are known to express SST
 
21–23
 
 and are included in the last classification
of NET.
 
24
 
 Parathyroid adenomas are also included in the classification
of NET and, in patients with MEN1, they share a common
pathogenic origin with gastro-entero-pancreatic NET and pituitary
adenomas.
 
1–3,24
 
Somatostatin pathway has been poorly investigated in parathyroid
tumours and perhaps SSA have been too early shelved as therapy for
PHP after their initial negative or inconclusive results with short-
acting octreotide. Neither a single acute administration nor a
short-time therapy with subcutaneous octreotide 200 
 
μ
 
g daily
induced beneficial changes in patients with PHP.
 
10–12
 
 Similarly, none
of these studies reported significant changes of serum and urinary
calcium concentrations. Only one case report showed improvement
Fig. 2 Variations of serum concentrations of PTH, calcium and phosphorus, 24-h urine calcium : creatinine (Ca/Cr) mg ratio, renal phosphate threshold 
(expressed as mean ± SEM) before (Time –3 and 0 month) and after (Time 3 and 6 months) therapy with octreotide LAR in eight patients with 
MEN1-dependent primary hyperparathyroidism.
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of hypercalcaemia
 
10
 
 and another study showed a significant decrease
of hypercalciuria and a mild but not significant improvement of
hypercalcaemia in 21 patients with PHP treated with octreotide
200 
 
μ
 
g daily for 6 days.
 
11
 
 In another patient with parathyroid
carcinoma, improvement of hypercalciuria during 2 weeks of
subcutaneous octreotide treatment was also reported.
 
25
 
 This effect
was completely reversible and retrieved upon discontinuation or
reintroduction, respectively, of octreotide.
 
25
 
 A few studies investigated
the effects of long-term SSA therapy in MEN1 patients. Recently, one
of two patients with MEN1-related PHP experienced decreased PTH
levels after 6 months of subcutaneous octreotide treatment.
 
13
 
 This
result was maintained after switching octreotide therapy from
subcutaneous to depot formulation. No effect was observed on PTH
levels in the second patient treated with OCT-LAR.
 
13
 
In the current study, we investigated the effects of long-term OCT-
LAR treatment on PTH excess and related electrolytic disorders in
a series of patients with MEN1 PHP. Our preliminary investigation
highlighted some intriguing findings. The use of a long-acting
slow-release SSA formulation for a longer period than in previous
studies, gave more convincing results.
 
10–12
 
 Serum PTH significantly
decreased in all of the patients and completely normalized in two of
them after 6 months of OCT-LAR therapy. Results were even more
evident on the biochemical abnormalities related to PTH excess. A
clear-cut and stable decrease of serum calcium concentrations and
urine calcium excretion was found after OCT-LAR therapy, resulting
in normalized serum and urinary calcium levels in 75% and 62·5%
of patients, respectively. At the same time, phosphate metabolism
improved, as documented by a significant increase of serum
phosphorus and renal threshold phosphate concentration. These
findings probably reflect remarkable renal effects of the overall
decrease in PTH secretion.
If the main biological effect of OCT-LAR on hyperparathyroidism
in patients with MEN1 is a likely direct antisecretive activity on
parathyroid adenomas, this effect may be mediated by SST activation.
Fig. 3 Variations of serum concentrations of PTH, calcium and phosphorus, 24-h urine calcium : creatinine (Ca/Cr) mg ratio, renal phosphate threshold 
(expressed as individual data) before (Time –3 and 0 month) and after (Time 3 and 6 month) therapy with octreotide LAR in eight patients with 
MEN1-dependent primary hyperparathyroidism.
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Immunohistochemistry for SST2A performed in three of the eight
cases demonstrated this SST subtype to be expressed in parathyroid
tumour cells. Furthermore, moderate-to-intense expression on the
cell membrane surface suggests the functional activity of SST2 in
parathyroid adenomas. In previous studies, autoradiography
revealed specific SST binding of radio-labelled octreotide in
peri-tumoral veins of parathyroid tumors
 
12
 
 but not in parathyroid
tumour cells.
 
26
 
 Furthermore, a positive somatostatin immunostain-
ing was reported in a case of parathyroid carcinoma which was
partially responsive to SSA treatment
 
25
 
 as well as in human parathyroid
adenomas.
 
27
 
In the current study, SST immunohistochemistry was not
concordant with the 
 
in vivo
 
 analysis of SST expression. SST scintigraphy
showed a low sensitivity in detecting parathyroid adenoma in MEN1
patients with PHP. The SST scintigraphy results were unrelated to
SST immunostaining as well as to the biochemical response to
OCT-LAR that occurred in either positive or negative patients at SST
scintigraphy. The low sensitivity of SST scintigraphy together with
its low ability in predicting the response to OCT-LAR may be
explained by small parathyroid tumour size and low density of SST
in tumour cells.
Besides the direct effects on PTH excess, exerted through specific
SST on parathyroid tumour cells, OCT-LAR may also affect
hyperparathyroidism and related electrolytic unbalances indirectly.
The decrease in urinary calcium excretion after OCT-LAR may be
in part PTH-independent and related to lowered intestinal calcium
absorption
 
28
 
 as a part of more general intestinal malabsorption
caused by long-term therapy with SSA.
 
29
 
 Moreover, OCT-LAR may
decrease intestinal absorption of calcium and consequently serum
calcium concentrations and renal excretion of calcium through the
inhibition of renal 1
 
α
 
-hydroxylase activity resulting in decreased
levels of 1,25-dihydroxyvitamin D. This effect may be further
enhanced by OCT-LAR-induced GH/IGF-I suppression, since GH
is known to increase renal synthesis of 1,25-dihydroxyvitamin D.
 
30
 
Although these indirect mechanisms may be partially responsible of
changes in calcium/phosphorus homeostasis, the main activity of
OCT-LAR in MEN1 patients with PHP is likely due to direct binding
to SST expressed on parathyroid tumour cells.
In conclusion, this study identifies multiple endocrine neoplasia
type 1-related primary hyperparathyroidism as a new potential
target for therapy with long-acting somatostatin analogues. Serum
PTH, calcium and phosphorus concentrations, urine calcium excretion
and renal tubular reabsorption of phosphorus resulted all stably
improved during a 6 month therapy with depot long acting octreotide.
SST expression on parathyroid tumour cells suggests that depot long
acting octreotide mainly improves calcium and phosphorus
abnormalities through direct effects on PTH hypersecretion.
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